- Voretigene Neparvovec (Spark Therapeutics): vision loss associated with biallelic RPE65-mediated retinal disease, January 2018 public meeting
- CAR-T Therapies, axicabtagene ciloleucel (Kite Pharmaceuticals) and tisagenlecleucel-t (Novartis): B-cell leukemia and lymphoma, March 2018 public meeting
- Apalutamide (Johnson & Johnson): prostate cancer
- CTP-modified human growth hormone (Opko/Pfizer): short stature/ growth hormone deficiency
- Damoctocog alfa pegol (Bayer), Emicizumab (Roche): hemophilia type A
- Erenumab (Amgen), fremanezumab (Teva), galcanezumab (Eli Lilly):migraine and other headaches
- Lanadelumab (Shire): hereditary angioedema
- Larotrectinib (LOXO Oncology/Array BioPharma): solid tumors expressing a specific biomarker
- Tezacaftor combination with ivacaftor (Vertex): cystic fibrosis
Final decisions for each drug will be made as we assign topics to one of ICER’s three public programs – California Technology Assessment Forum (CTAF), New England Comparative Effectiveness Public Advisory Council (New England CEPAC), or the Midwest CEPAC. The next topic announcement is scheduled for mid-August. Topic suggestions are always welcome. Submissions can be made via this online form.
ICER’s reports incorporate extensive input from all stakeholders and are the subject of public hearings through three core programs: the California Technology Assessment Forum (CTAF), the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), and the New England Comparative Effectiveness Public Advisory Council (New England CEPAC). These independent panels review ICER’s reports at public meetings to deliberate on the evidence and develop recommendations for how patients, clinicians, insurers, and policymakers can improve the quality and value of health care. For more information about ICER, please visit ICER’s website.